Early-Career Members Join NMD4C Working Groups

The NMD4C is happy to announce that six early-career network members have been appointed to leadership roles on three NMD4C working groups: Biobanking, Early-Career, and Knowledge Translation. 

The network looks forward to the valuable input and broadened perspective that each member has or will provide to these network activities, and would like to welcome the following early-career members to our working groups:

The NMD4C are committed to empowering the next generation of  early-career researchers and clinicians in building successful careers in neuromuscular disease research and clinical practice. Providing early-career leadership opportunities within the network will not only amplify the early-career perspective and help to inform the network’s activities, but also empowers our members to become future leaders in the neuromuscular community. 

Other opportunities that the NMD4C provides for early-career members include:

  • Sharing blog posts from early-career members
  • Research and clinical fellowship funding opportunities
  • Webinars and events tailored to early-career audience

If you are an early-career researcher or clinician, please feel free to visit our early-career page or contact James Davis at if you are interested in further engagement with the network.

new WG members

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.